Lori S. Hart

4.2k total citations · 1 hit paper
27 papers, 1.8k citations indexed

About

Lori S. Hart is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Lori S. Hart has authored 27 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Neurology. Recurrent topics in Lori S. Hart's work include Neuroblastoma Research and Treatments (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer Research and Treatments (6 papers). Lori S. Hart is often cited by papers focused on Neuroblastoma Research and Treatments (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer Research and Treatments (6 papers). Lori S. Hart collaborates with scholars based in United States, Ireland and Australia. Lori S. Hart's co-authors include Constantinos Koumenis, Wafik S. El‐Deiry, Jiangbin Ye, Kelly L. Sloane, Haiyan Zhang, David Ron, J. Alan Diehl, Ekaterina Bobrovnikova-Marjon, David T. Dicker and John M. Maris and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Lori S. Hart

26 papers receiving 1.8k citations

Hit Papers

The GCN2‐ATF4 pathway is critical for tumour cell surviva... 2010 2026 2015 2020 2010 100 200 300 400 500

Peers

Lori S. Hart
José Grenet United States
Arturo Sala United Kingdom
Rachel A. Altura United States
Lori S. Hart
Citations per year, relative to Lori S. Hart Lori S. Hart (= 1×) peers Alexander Valent

Countries citing papers authored by Lori S. Hart

Since Specialization
Citations

This map shows the geographic impact of Lori S. Hart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori S. Hart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori S. Hart more than expected).

Fields of papers citing papers by Lori S. Hart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori S. Hart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori S. Hart. The network helps show where Lori S. Hart may publish in the future.

Co-authorship network of co-authors of Lori S. Hart

This figure shows the co-authorship network connecting the top 25 collaborators of Lori S. Hart. A scholar is included among the top collaborators of Lori S. Hart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori S. Hart. Lori S. Hart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gruber, Joshua J., Ulrike Litzenburger, Yu Rebecca Miao, et al.. (2020). Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia. Cell Death and Disease. 11(2). 102–102. 47 indexed citations
2.
Sussman, Robyn T., Jo Lynne Rokita, Pichai Raman, et al.. (2020). CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma. Frontiers in Oncology. 10. 302–302. 11 indexed citations
3.
Tamir, Jonathan I., Valentina Taviani, Marcus T. Alley, et al.. (2019). Targeted rapid knee MRI exam using T2 shuffling. Journal of Magnetic Resonance Imaging. 49(7). e195–e204. 11 indexed citations
4.
Harenza, Jo Lynne, Maura Diamond, Rebecca N. Adams, et al.. (2017). Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Scientific Data. 4(1). 110 indexed citations
5.
Ashique, Amir M., Lori S. Hart, C. David L. Thomas, et al.. (2017). Lacunar-canalicular network in femoral cortical bone is reduced in aged women and is predominantly due to a loss of canalicular porosity. Bone Reports. 7. 9–16. 57 indexed citations
6.
Hart, Lori S., JulieAnn Rader, Pichai Raman, et al.. (2016). Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research. 23(7). 1785–1796. 57 indexed citations
7.
Wood, Andrew, Kateryna Krytska, Hannah T. Ryles, et al.. (2016). Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. Clinical Cancer Research. 23(11). 2856–2868. 67 indexed citations
8.
Rader, JulieAnn, Mike R. Russell, Lori S. Hart, et al.. (2013). Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research. 19(22). 6173–6182. 308 indexed citations
9.
Guttmann, David, et al.. (2013). Inhibition of Hsp27 Radiosensitizes Head-and-Neck Cancer by Modulating Deoxyribonucleic Acid Repair. International Journal of Radiation Oncology*Biology*Physics. 87(1). 168–175. 18 indexed citations
10.
Mayes, Patrick A., Nathan G. Dolloff, Colin J. Daniel, et al.. (2011). Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3β and CDK1. Cancer Research. 71(15). 5265–5275. 27 indexed citations
11.
Finnberg, Niklas K., Lori S. Hart, Nathan G. Dolloff, et al.. (2011). High-Resolution Imaging and Antitumor Effects of GFP+ Bone Marrow-Derived Cells Homing to Syngeneic Mouse Colon Tumors. American Journal Of Pathology. 179(5). 2169–2176. 3 indexed citations
12.
Hart, Lori S., Howard A. Burris, J. R. Infante, et al.. (2011). mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.. Journal of Clinical Oncology. 29(15_suppl). e14054–e14054. 4 indexed citations
13.
Ye, Jiangbin, Lori S. Hart, Kelly L. Sloane, et al.. (2010). The GCN2‐ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. The EMBO Journal. 29(12). 2082–2096. 552 indexed citations breakdown →
14.
Matthew, Elizabeth, Lori S. Hart, Aristotelis Astrinidis, et al.. (2009). The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions. Cell Cycle. 8(24). 4168–4175. 54 indexed citations
15.
Allen, Joshua E., Lori S. Hart, David T. Dicker, Wenge Wang, & Wafik S. El‐Deiry. (2009). Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biology & Therapy. 8(22). 2193–2204. 14 indexed citations
17.
Park, Margaret A., Adly Yacoub, Mohamed Rahmani, et al.. (2008). OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells. Molecular Pharmacology. 73(4). 1168–1184. 62 indexed citations
18.
Hart, Lori S., et al.. (2007). Effects of Low Confluency, Serum Starvation and Hypoxia on the Side Population of Cancer Cell Lines. Cell Cycle. 6(20). 2554–2562. 67 indexed citations
20.
Hart, Lori S., Steven M. Yannone, Christine Naczki, et al.. (2004). The Adenovirus E4orf6 Protein Inhibits DNA Double Strand Break Repair and Radiosensitizes Human Tumor Cells in an E1B-55K-independent Manner. Journal of Biological Chemistry. 280(2). 1474–1481. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026